The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
Open accessAbstract
BACKGROUND: The worst Ebola virus disease (EVD) outbreak in history has resulted in more than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an attenuated, replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate designed to prevent EVD. METHODS: We conducted two phase 1, placebo-controlled, double-blind, dose-escalation trials of an rVSV-based vaccine candidate expressing the glycoprotein of a Zaire strain of Ebola virus (ZEBOV). A total of 39 adults at each site (78 participants in all) were consecutively enrolled into groups of 13. At each site, volunteers received one of three doses of the rVSV-ZEBOV vaccine (3 million plaque-forming units [PFU], 20 million PFU, or 100 million PFU) or placebo. Volunteers at one of the sites received a second dose at day 28. Safety and immunogenicity were assessed. RESULTS: The most common adverse events were injection-site pain, fatigue, myalgia, and headache. Transient rVSV viremia was noted in all the vaccine recipients after dose 1. The rates of adverse events and viremia were lower after the second dose than after the first dose. By day 28, all the vaccine recipients had seroconversion as assessed by an enzyme-linked immunosorbent assay (ELISA) against the glycoprotein of the ZEBOV-Kikwit strain. At day 28, geometric mean titers of antibodies against ZEBOV glycoprotein were higher in the groups that received 20 million PFU or 100 million PFU than in the group that received 3 million PFU, as assessed by ELISA and by pseudovirion neutralization assay. A second dose at 28 days after dose 1 significantly increased antibody titers at day 56, but the effect was diminished at 6 months. CONCLUSIONS: This Ebola vaccine candidate elicited anti-Ebola antibody responses. After vaccination, rVSV viremia occurred frequently but was transient. These results support further evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost antibody responses. (Funded by the National Institutes of Health and others; rVSV∆G-ZEBOV-GP ClinicalTrials.gov numbers, NCT02269423 and NCT02280408 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., Carroll, M. W., Dean, N. E., Diatta, I., Doumbia, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32621-6 · Cited by 1,110
Henao-Restrepo, A. M., Longini, I. M., Egger, M., Dean, N. E., Edmunds, W. J., Camacho, A., Carroll, M. W., Doumbia, M., Draguez, B., Duraffour, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61117-5 · Cited by 793
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
Jones, S. M., Feldmann, H., Ströher, U., Geisbert, J. B., Fernando, L., Grolla, A., Klenk, H.-D., Sullivan, N. J., Volchkov, V. E., Fritz, E. A., et al. (2005) · Nature Medicine · doi:10.1038/nm1258 · Cited by 687
Self-citationPhase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
Agnandji, S. T., Huttner, A., Zinser, M. E., Njuguna, P., Dahlke, C., Fernandes, J. F., Yerly, S., Dayer, J.-A., Kraehling, V., Kasonta, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1502924 · Cited by 412
Self-citationGarbutt, M., Liebscher, R., Wahl-Jensen, V., Jones, S., Möller, P., Wagner, R., Volchkov, V., Klenk, H.-D., Feldmann, H., & Ströher, U. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5458-5465.2004 · Cited by 381
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E. B., Payne, R., Fehling, S. K., Strecker, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1411627 · Cited by 348
Self-citationEffective Post-Exposure Treatment of Ebola Infection
Feldmann, H., Jones, S. M., Daddario-DiCaprio, K. M., Geisbert, J. B., Ströher, U., Grolla, A., Bray, M., Fritz, E. A., Fernando, L., Feldmann, F., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030002 · Cited by 288
Chimpanzee Adenovirus Vector Ebola Vaccine
Ledgerwood, J. E., DeZure, A. D., Stanley, D. A., Coates, E. E., Novik, L., Enama, M. E., Berkowitz, N. M., Hu, Z., Joshi, G., Ploquin, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1410863 · Cited by 285
Self-citationGeisbert, T. W., Geisbert, J. B., Leung, A., Daddario-DiCaprio, K. M., Hensley, L. E., Grolla, A., & Feldmann, H. (2009) · Journal of Virology · doi:10.1128/jvi.00561-09 · Cited by 275
Huttner, A., Dayer, J.-A., Yerly, S., Combescure, C., Auderset, F., Desmeules, J., Eickmann, M., Finckh, A., Goncalves, A. R., Hooper, J. W., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00154-1 · Cited by 272
Self-citationChimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1505499 · Cited by 248
Recombinant Vesicular Stomatitis Virus–Based Vaccines Against Ebola and Marburg Virus Infections
Geisbert, T. W., & Feldmann, H. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir349 · Cited by 230
Sullivan, N. J., Geisbert, T. W., Geisbert, J. B., Shedlock, D. J., Xu, L., Lamoreaux, L., Custers, J. H. H. V., Popernack, P. M., Yang, Z.-Y., Pau, M. G., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030177 · Cited by 205
Self-citationGeisbert, T. W., Daddario-DiCaprio, K. M., Geisbert, J. B., Reed, D. S., Feldmann, F., Grolla, A., Ströher, U., Fritz, E. A., Hensley, L. E., Jones, S. M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.082 · Cited by 197
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates
Johnson, J. E., Nasar, F., Coleman, J. W., Price, R. E., Javadian, A., Draper, K., Lee, M., Reilly, P. A., Clarke, D. K., Hendry, R. M., et al. (2007) · Virology · doi:10.1016/j.virol.2006.10.026 · Cited by 160
Wong, G., Richardson, J. S., Pillet, S., Patel, A. R., Qiu, X., Alimonti, J. B., Hogan, J., Zhang, Y., Takada, A., Feldmann, H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004582 · Cited by 160
Self-citationDemonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species
Hensley, L. E., Mulangu, S., Asiedu, C. K., Johnson, J. C., Honko, A. N., Stanley, D. A., Fabozzi, G., Nichol, S. T., Ksiazek, T. G., Rollin, P. E., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000904 · Cited by 157
Self-citationQiu, X., Fernando, L., Alimonti, J. B., Melito, P. L., Feldmann, F., Dick, D., Ströher, U., Feldmann, H., & Jones, S. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005547 · Cited by 147
Self-citationFunctional Importance of the Coiled-Coil of the Ebola Virus Glycoprotein
Watanabe, S., Takada, A., Watanabe, T., Ito, H., Kida, H., & Kawaoka, Y. (2000) · Journal of Virology · doi:10.1128/jvi.74.21.10194-10201.2000 · Cited by 131
Lai, L., Davey, R. T., Beck, A., Xu, Y., Suffredini, A. F., Palmore, T. N., Kabbani, S., Rogers, S., Kobinger, G., Alimonti, J. B., et al. (2015) · JAMA · doi:10.1001/jama.2015.1995 · Cited by 91
Self-citationDurability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates
Mire, C. E., Geisbert, J. B., Agans, K. N., Satterfield, B. A., Versteeg, K. M., Fritz, E. A., Feldmann, H., Hensley, L. E., & Geisbert, T. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094355 · Cited by 87
Kugelman, J. R., Sánchez-Lockhart, M., Andersen, K. G., Gire, S., Park, D. J., Sealfon, R. S. G., Lin, A. E., Wohl, S., Sabeti, P. C., Kuhn, J. H., et al. (2015) · mBio · doi:10.1128/mbio.02227-14 · Cited by 67
Cited by
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., Carroll, M. W., Dean, N. E., Diatta, I., Doumbia, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32621-6 · Cited by 1,110
Henao-Restrepo, A. M., Longini, I. M., Egger, M., Dean, N. E., Edmunds, W. J., Camacho, A., Carroll, M. W., Doumbia, M., Draguez, B., Duraffour, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61117-5 · Cited by 793
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Metadata
- Authors
- Regules, J. A., Beigel, J. H., Paolino, K. M., Voell, J., Castellano, A. R., Hu, Z., Muñoz, P., Moon, J. E., Ruck, R. C., Bennett, J. W., Twomey, P. S., Gutiérrez, R. L., Remich, S. A., Hack, H. R., Wisniewski, M. L., Josleyn, M. D., Kwilas, S. A., Van Deusen, N., Mbaya, O. T., Zhou, Y., Stanley, D. A., Jing, W., Smith, K. S., Shi, M., Ledgerwood, J. E., Graham, B. S., Sullivan, N. J., Jagodzinski, L. L., Peel, S. A., Alimonti, J. B., Hooper, J. W., Silvera, P. M., Martin, B. K., Monath, T. P., Ramsey, W. J., Link, C. J., Lane, H. C., Michael, N. L., Davey, R. T., & Thomas, S. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-01-26
- Volume
- 376
- Issue
- 4
- Pages
- 330-341
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152076520
- Cited by
- 387
- References
- 22
- FWCI
- 39.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.